LFA
VRTX icon

Legacy Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Sell
3,139
-5
-0.2% -$2.22K 0.19% 88
2026
Q1 		$1.4M Buy
3,144
+169
+6% +$78.8K 0.2% 92
2025
Q4 		$1.35M Buy
2,975
+49
+2% +$21.1K 0.19% 97
2025
Q3 		$1.15M Sell
2,926
-55
-2% -$23K 0.16% 103
2025
Q2 		$1.33M Sell
2,981
-105
-3% -$48.4K 0.21% 79
2025
Q1 		$1.5M Buy
3,086
+534
+21% +$249K 0.25% 69
2024
Q4 		$1.03M Buy
2,552
+104
+4% +$48.2K 0.17% 104
2024
Q3 		$1.14M Buy
2,448
+25
+1% +$12K 0.19% 89
2024
Q2 		$1.14M Buy
2,423
+117
+5% +$50.8K 0.2% 79
2024
Q1 		$964K Buy
2,306
+147
+7% +$62.1K 0.17% 96
2023
Q4 		$878K Buy
2,159
+232
+12% +$85.7K 0.17% 91
2023
Q3 		$670K Buy
1,927
+376
+24% +$132K 0.13% 100
2023
Q2 		$546K Buy
1,551
+163
+12% +$54.9K 0.1% 127
2023
Q1 		$437K Buy
1,388
+92
+7% +$27.6K 0.09% 141
2022
Q4 		$374K Buy
1,296
+26
+2% +$7.92K 0.08% 146
2022
Q3 		$368K Buy
1,270
+116
+10% +$33.4K 0.09% 133
2022
Q2 		$325K Buy
1,154
+170
+17% +$45.5K 0.08% 139
2022
Q1 		$257K Buy
+984
New +$234K 0.06% 193
2019
Q2 		– Sell
-149
Closed -$27K – 886
2019
Q1 		$27K Buy
149
+23
+18% +$4.25K 0.01% 402
2018
Q4 		$21K Buy
126
+116
+1,160% +$20.1K 0.01% 406
2018
Q3 		$1K Hold
10
– – ﹤0.01% 864
2018
Q2 		$2K Sell
10
-43
-81% -$6.67K ﹤0.01% 840
2018
Q1 		$8K Buy
53
+48
+960% +$7.84K ﹤0.01% 551
2017
Q4 		$0 Buy
+5
New +$740 ﹤0.01% 861

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Legacy Financial Advisors's VRTX Position: Q2 2026 in Review

Legacy Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.16% in Q2 2026, selling an estimated $2.22K and leaving 3,139 shares worth $1.56M. The position accounts for 0.19% of the portfolio, ranked #88.

Legacy Financial Advisors first reported a position in VRTX in Q4 2017 and has held it in 24 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Legacy Financial Advisors held 3,139 shares of Vertex Pharmaceuticals worth $1.56M as of Q2 2026.
  • Legacy Financial Advisors sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
  • Vertex Pharmaceuticals made up 0.19% of Legacy Financial Advisors's portfolio in Q2 2026, its #88 holding.
  • Legacy Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 24 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Financial Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.